home / stock / arqt / arqt news

ARQT News and Press, Arcutis Biotherapeutics Inc. From 10/19/23

Stock Information
Company Name: Arcutis Biotherapeutics Inc.
Stock Symbol: ARQT
Market: NASDAQ
Website: arcutis.com
Menu
ARQT ARQT Quote ARQT Short ARQT News ARQT Articles ARQT Message Board
Get ARQT Alerts

News, Short Squeeze, Breakout and More Instantly...
ARQT - Arcutis Announces Pricing of $100 Million Public Offering

WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritt...
ARQT - Arcutis stock slips on $100M proposed public offering

2023-10-19 16:14:32 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation For further details see: Arcutis stock slips on $100M propose...

ARQT - Arcutis Announces Proposed Public Offering

WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the commencement of an underwritten public offe...

ARQT - Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

Once-daily, steroid-free roflumilast foam 0.3% demonstrated significant improvements in both scalp and body psoriasis across all efficacy endpoints compared to vehicle New data highlights a significant reduction in scalp itch observed as early as 24 hours following the first application of ro...
ARQT - Arcutis granted FDA label expansion for Zoryve psoriasis therapy

2023-10-06 09:06:09 ET More on Arcutis Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Arcutis: Zoryve - A Challenging Launch With Progress Arcutis posts late-s...

ARQT - FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approve...

ARQT - Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

Industry veteran with deep commercial experience in dermatology and immunology Ayisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial...
ARQT - New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

WESTLAKE VILLAGE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of an educational campaign designed to elevate understanding,...

ARQT - Arcutis posts late-stage win for atopic dermatitis therapy in children

2023-09-19 08:22:32 ET More on Arcutis Seeking Alpha’s Quant Rating on Arcutis Biotherapeutics Historical earnings data for Arcutis Biotherapeutics Arcutis: Zoryve - A Challenging Launch With Progress Arcutis Biotherapeutics: High OpEx And Crowded Mark...

ARQT - Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials For the primary endpoint, 25.4% of children treated once daily with roflumilast cream 0.05% achieved Investigator Global Assessment (IGA) S...
Previous 10 Next 10